Warner Chilcott to acquire topical drug from NexMed
WCRX | Quote | Chart | News | PowerRating -- Warner Chilcott Company, a subsidiary of Warner Chilcott, has entered into an agreement with NexMed, a pharmaceutical and medical technology company, to acquire the US rights of NexMed's topically applied alprostadil cream for the treatment of erectile dysfunction.
As a result, the previous licensing agreement between Warner Chilcott and NexMed related to this product has been terminated.
Under the terms of the agreement, NexMed received an up-front payment of $2.5 million and is eligible to receive an additional payment of $2.5 million upon Warner Chilcott's receipt of a new drug application approval from the FDA. In addition, Warner Chilcott will pay a total of $350,000 for the manufacturing equipment for the product.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on Warner Chilcott Ltd Cl A (WCRX) WCRX. Warner Chilcott Ltd Cl A (WCRX) has Short Term PowerRatings at TradingMarkets. Details on Warner Chilcott Ltd Cl A (WCRX) Short Term PowerRatings is available at This Link.
- Warner Chilcott Provides Mixed Guidance - 01/29/10
- Warner Chilcott Announces 2010 Financial Guidance - 01/29/10
- Analyst Downgrades for January 28th - 01/28/10
- Warner Chilcott obtains FDA complete response letter for contraception drug - 01/28/10
- FDA Issues Complete Response Letter for Low Dose Oral Contraceptive - 01/27/10
- More News >>


